A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache

NCT02797951 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

165

Enrollment

INDUSTRY

Sponsor class

Conditions

Episodic Cluster Headache
Chronic Cluster Headache

Interventions

DRUG: Galcanezumab

Sponsor

Eli Lilly and Company